The Journal of Rheumatology最新文献_第3页

Do monosodium urate crystals reduce at different rates in joints and tendons during urate-lowering therapy? A dual energy CT study. 在降尿酸治疗期间，尿酸钠晶体在关节和肌腱中是否以不同的速率减少？双能CT研究。

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0122

Waimarama Mulqueen,Greg Gamble,Anthony Doyle,Borislav Mihov,Anne Horne,Jill Drake,Lisa K Stamp,Nicola Dalbeth

{"title":"Do monosodium urate crystals reduce at different rates in joints and tendons during urate-lowering therapy? A dual energy CT study.","authors":"Waimarama Mulqueen,Greg Gamble,Anthony Doyle,Borislav Mihov,Anne Horne,Jill Drake,Lisa K Stamp,Nicola Dalbeth","doi":"10.3899/jrheum.2025-0122","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0122","url":null,"abstract":"OBJECTIVEPrior imaging studies have suggested that MSU crystal deposits in joints dissolve more rapidly than those in tendons during urate-lowering therapy for gout. This study aimed to examine whether urate deposits visible on dual energy CT (DECT) reduce at different rates in joints and tendons during urate-lowering therapy.METHODSParticipants with gout from two clinical trials of oral urate-lowering therapy with the following criteria were included: paired DECT scans of the feet and ankles over one-year of urate-lowering therapy, first DECT scan showing total urate volume ≥0.5cm3, second DECT scan showing reduced total urate volume, and DECT deposition visible in at least one joint and one tendon on the first scan. DECT urate volumes in up to three index joints and up to three index tendons at baseline and Year 1 were measured in known order. Data were analyzed using a general linear mixed analysis of covariance (ANCOVA).RESULTSIn total, 125 joint deposits and 95 tendon deposits were analyzed from 50 participants. The least means (95% CI) change in DECT urate volumes of the joint deposits was -0.37 (-0.47 to -0.26) cm3 and of the tendon deposits was -0.39 (-0.50 to -0.27) cm3, both P<0.001. There was no difference in the change in DECT urate volumes between the joint and tendon deposits; least means (95% CI) difference was 0.02 (-0.09 to 0.13) cm3, P=0.73.CONCLUSIONThis DECT study indicates that similar rates of monosodium urate crystal dissolution occur at both joints and tendons during oral urate-lowering therapy.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cotton-Wool Appearance of Muscular Polyarteritis Nodosa on Contrast Magnetic Resonance Imaging. 肌性结节性多动脉炎的mri棉样表现。

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0771

Maho Hatano,Hitoshi Irabu,Yuko Hayashi,Masaki Shimizu

引用次数: 0

Improving Mental Health Care for People With Systemic Lupus Erythematosus: Time to Take Action. 改善系统性红斑狼疮患者的心理健康护理：是时候采取行动了。

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0922

Tamar B Rubinstein,Zahi Touma,Irene Blanco,Andrea M Knight

引用次数: 0

Long-term epidemiology of Systemic Sclerosis in Western Australia: a population-level linked data study. 西澳大利亚系统性硬化症的长期流行病学：一项人口水平的相关数据研究。

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0525

Lauren V Host,Derrick Lopez,Helen I Keen,David Preen,Charles Inderjeeth,Johannes Nossent

{"title":"Long-term epidemiology of Systemic Sclerosis in Western Australia: a population-level linked data study.","authors":"Lauren V Host,Derrick Lopez,Helen I Keen,David Preen,Charles Inderjeeth,Johannes Nossent","doi":"10.3899/jrheum.2025-0525","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0525","url":null,"abstract":"OBJECTIVETo report prevalence, incidence and mortality of Systemic Sclerosis (SSc) in Western Australia (WA).METHODSRetrospective observational study, using whole-population linked administrative health data from the Western Australia Rheumatic Disease Epidemiological Registry (WARDER). All patients with an incident (first-ever) hospitalisation with SSc between 1985-2013 identified from discharge diagnosis fields and followed until end of 2014. Outcome measures were incidence rates (IR), point prevalence, standardised mortality ratio (SMR) and survival estimates using Cox regression, stratified by gender.RESULTSIn total 877 patients (mean age 58.6 years, 77.5% female, 3.2% Indigenous) had an incident hospitalisation for SSc. The aged-standardised IR of SSc ranged from 0.44 to 3.26 per 100,000 person-years and point prevalence averaged 37.93 per 100,000 population; both were higher for females. During the study period 452 (51.5%) patients died with crude mortality higher in males than females (66.2% vs 47.4%; p<0.001). The SMR was 4.17 (3.81-4.58) while five and ten-year survival rates were 67.0 % and 52.4% respectively. Age (HR=1.05; 95% CI:1.04-1.05), male sex (HR=1.56; 95% CI 1.26-1.92), heart failure (HR=1.88; 95% CI: 1.35-2.60), kidney disease (HR=1.71; 95% CI: 1.13-2.58) and cancer (HR=1.88: 95% CI: 1.30-2.74) were independently associated with death. The main causes of death were SSc (n=128, 28.3%), solid organ malignancy (n=65, 14.4%) and ischaemic heart disease (n=47; 10.4%).CONCLUSIONThe burden of SSc in WA exceeds global estimates where its high prevalence, high SMR and number of deaths due to SSc as a primary cause suggest a large unmet therapeutic need.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"76 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calcium Pyrophosphate Crystals of the Brachial Plexus: A Case Report. 臂神经丛焦磷酸钙晶体一例报告。

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0529

Alex M Tinianow,Minna J Kohler,Derek M Loneman,Janeth M Yinh

引用次数: 0

Association of Frailty with Risk of Osteoarthritis Development, Progression and Worse Clinical Outcomes in Older Adults. 老年人骨关节炎发生、进展和较差临床结果与虚弱的关系

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0578

Jocelyn Waghorn,Selena P Maxwell,Sophie E Rayner,Rebecca Moyer,Kenneth Rockwood,Olga Theou,Maroun Rizkallah,Alexandra Legge,Myles W O'Brien

{"title":"Association of Frailty with Risk of Osteoarthritis Development, Progression and Worse Clinical Outcomes in Older Adults.","authors":"Jocelyn Waghorn,Selena P Maxwell,Sophie E Rayner,Rebecca Moyer,Kenneth Rockwood,Olga Theou,Maroun Rizkallah,Alexandra Legge,Myles W O'Brien","doi":"10.3899/jrheum.2025-0578","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0578","url":null,"abstract":"OBJECTIVEBoth frailty and osteoarthritis become common with aging. Given their shared age-related incidence, we hypothesized that greater baseline frailty, measured by frailty index, would be associated with worse osteoarthritis outcomes, including higher incidence, poorer Knee Injury and Osteoarthritis Outcome Score (KOOS) trajectories, increased fall risk, and higher rates of total or partial knee (KA) or hip (HA) arthroplasty in middle-aged and older adults.METHODSA frailty index score was calculated for 4753 participants (58.53% females; mean age 61.2, 95% CI: 60.94-61.46) from the Osteoarthritis Initiative (OAI) broken into control, incidence, and progression groups. Longitudinal OAI outcomes including incidence, KOOS progression, falls, and KA/HA were extracted for ~9 years from baseline.RESULTSHigher baseline frailty was associated with development of osteoarthritis by three-, five- and nine-year follow-up (all, p<0.001) with greatest impact at nine years (OR: 1.73, 95% CI: 1.52-1.97, p<0.001). Disease trajectory, as measured by KOOS subscale scores, was negatively influenced by increasing frailty (all, p<0.001), the greatest impact being on KOOS Function (Estimate: -9.52, 95% CI: -10.28 to -8.77, p<0.001). A 0.1 difference in baseline frailty index scores was associated with increase in the odds of experiencing a fall within 3-years of baseline (OR: 1.44, 95% CI: 1.32-1.58, p<0.001). Regardless of surgical site, frailty index scores did not significantly impact risk of experiencing KA/HA except in females undergoing HA (HR: 1.29, 95% CI: 1.04-1.61, p=0.02).CONCLUSIONFrailty was associated with greater risk of osteoarthritis incidence and falls, as well as KOOS-measured disease progression, but not joint-replacement surgery-free time.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"98 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe Symptoms Predict Residual Disease After Transitioning From High to Low Disease Activity in Axial Spondyloarthritis: A Longitudinal Study. 轴型脊柱炎从高活动性到低活动性转变后，严重症状预示残留疾病：一项纵向研究。

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0421

Marius L Smits,Ellen Renet,Harald E Vonkeman,Casper Webers,Astrid van Tubergen

{"title":"Severe Symptoms Predict Residual Disease After Transitioning From High to Low Disease Activity in Axial Spondyloarthritis: A Longitudinal Study.","authors":"Marius L Smits,Ellen Renet,Harald E Vonkeman,Casper Webers,Astrid van Tubergen","doi":"10.3899/jrheum.2025-0421","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0421","url":null,"abstract":"OBJECTIVETo investigate whether very high disease activity (VHDA) status or severe symptoms when in HDA state predict residual disease after achieving inactive disease/low disease activity (ID/LDA) in axial spondyloarthritis (axSpA).METHODSProspective data from the SpA-Net registry were used. HDA was defined as an Axial Spondyloarthritis Disease Activity Score (ASDAS)≥2.1, and ID/LDA as ASDAS<2.1. VHDA (predictor 1) was defined as ASDAS>3.5, and severe symptoms when in HDA state (predictor 2) as a score ≥6/10 for fatigue, back pain and/or physical function. Residual disease (outcome) was defined as presence of ≥1 patient-experienced (fatigue, back pain and/or physical function ≥4/10) or objective disease indicator (active peripheral manifestations, active psoriasis, elevated C-reactive protein or physician's impression) after achieving ID/LDA. Associations between either predictor and residual disease were investigated using logistic regression.RESULTSOverall, 133 patients (58 [43.6%] female, mean age 48.8 [SD 14.5] years) were included. At the HDA time-point, 16 (12.0%) patients had VHDA status and 107 (80.5%) experienced severe symptoms. At the ID/LDA time-point, prevalence of patient-experienced and objective residual disease was 70.7% (n=94/133) and 54% (n=37/68), respectively. VHDA status when in HDA state was not associated with either form of residual disease after achieving ID/LDA. Severe symptoms were associated with patient-experienced residual disease (OR=5.09 [95%CI 1.76-14.71]), but not objective residual disease.CONCLUSIONSevere symptoms when in HDA state predict patient-experienced, but not objective, residual disease in axSpA, while VHDA status does not predict either form. These findings may aid in anticipating residual disease and guiding management.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"76 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GRAPPA 2024 Meeting: Advances in Psoriatic Disease Research From Pilot Grant Awardees. GRAPPA 2024会议：银屑病研究进展

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0876

Keith Colaco,Omar Alzayat,Steven Dang,Caroline Gross,Philip S Helliwell,Paras Karmacharya,David Simon,Axel Svedbom,Vinod Chandran,Wilson Liao,Kurt de Vlam

{"title":"GRAPPA 2024 Meeting: Advances in Psoriatic Disease Research From Pilot Grant Awardees.","authors":"Keith Colaco,Omar Alzayat,Steven Dang,Caroline Gross,Philip S Helliwell,Paras Karmacharya,David Simon,Axel Svedbom,Vinod Chandran,Wilson Liao,Kurt de Vlam","doi":"10.3899/jrheum.2025-0876","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0876","url":null,"abstract":"Prioritizing and supporting trainee research in psoriatic disease (PsD) is a cornerstone of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Each year, trainees and junior faculty are invited to submit proposals to GRAPPA to fund pilot research projects related to psoriasis or psoriatic arthritis. Projects can be in any of the following 4 categories: clinical science, translational science, basic science research, or combined PsD. GRAPPA remains committed to showcasing the trainee research supported by these grants at the annual meeting. The GRAPPA 2024 annual meeting and trainee symposium was held in Seattle, Washington, USA; a meeting highlight was the session dedicated to the pilot research grant projects led by trainees and faculty. This year, 27 submissions were received from 14 countries across North America, Europe, and Asia. Compared to prior years, an updated grant review process enhanced efficiency and created more opportunities for conversation among evaluators. A panel of 14 GRAPPA reviewers assessed the submissions, ultimately selecting 4 projects for funding. This meeting report aims to summarize the 2024 pilot research grant recipients and the project results from past grant recipients.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smoking Cessation and Gout Risk in Indigenous Populations: A Call for Causal Inference and Multiethnic Mendelian Randomization. 土著人群中戒烟和痛风风险：对因果推理和多民族孟德尔随机化的呼吁。

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0193

Ran Xiong,Long Chen

引用次数: 0

Navigating the Roadblocks: National Patient and Provider Survey on Barriers to Healthcare and Medication Access for Patients with Vasculitis. 导航障碍：国家患者和提供者调查的障碍，医疗保健和药物获取的血管炎患者。

The Journal of Rheumatology Pub Date : 2025-10-01 DOI: 10.3899/jrheum.2025-0640

Kareena Nanda,Pamela Mathura,Katharina Kovacs Burns,Christian Pagnoux,Jon Stewart,Elaine Yacyshyn

{"title":"Navigating the Roadblocks: National Patient and Provider Survey on Barriers to Healthcare and Medication Access for Patients with Vasculitis.","authors":"Kareena Nanda,Pamela Mathura,Katharina Kovacs Burns,Christian Pagnoux,Jon Stewart,Elaine Yacyshyn","doi":"10.3899/jrheum.2025-0640","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0640","url":null,"abstract":"OBJECTIVETimely diagnosis, specialized care, and medication access are critical for managing vasculitis. This study quantified barriers to care reported by patients and healthcare providers (HCPs).METHODSTwo primarily quantitative surveys were disseminated from September 2022 to June 2023 to 100 patients with vasculitis and 31 HCPs, through the Vasculitis Foundation Canada and the Canadian Rheumatology Association. This study was a secondary descriptive analysis of the data to analyze patient and HCP perspectives on diagnostic delays, appointment access, and medication challenges.RESULTSDiagnostic delays were common, with 66% of patients reporting initial 'misdiagnoses', and 36% consulting ≥5 doctors before receiving a diagnosis of vasculitis. Among those referred to rheumatology, 57% waited >1 month for an appointment. HCPs cited a lack of family physicians (74%), long waitlists (58%), and inappropriate referrals (48%) as major barriers. Forty-four percent of patients reported challenges associated with medication use, particularly related to adverse effects, out-of-pocket costs, and limited insurance coverage. Eighty-three percent of patients reported hospital visits at least once for vasculitis-related symptoms, most commonly due to disease flare. Ninety-three percent of HCPs reported facing medication access barriers, including challenges associated with prior authorizations and step therapy protocols, with rituximab most frequently cited as difficult to access.CONCLUSIONThis study identified substantial barriers to vasculitis care, including diagnostic delays and limited access to medications. Targeted interventions, such as improving referral pathways, expanding provider availability, and reducing administrative burdens, are essential to improving access for this vulnerable population.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"124 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0